Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40012036
Localisation
United Kingdom
Europe
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
11/07/2024
Statut
Classification
1.5°C
Année cible
FY2032
Statut
Targets set
Classification
1.5°C
Année cible
FY2045
Overall Net-Zero Target: Eisai Europe Limited commits to reach net-zero greenhouse gas emissions across the value chain by FY2045. Near-Term Targets: Eisai Europe Limited commits to reduce absolute scope 1 and 2 GHG emissions 62% by FY2032 from a FY2022 base year. Eisai Europe Limited also commits to reduce absolute scope 3 GHG emissions 41% within the same timeframe. Eisai Europe Limited further commits to increase active annual sourcing of renewable electricity from 98% in FY2022 to 100% by FY2030. Long-Term Targets: Eisai Europe Limited commits to reduce absolute scope 1 and 2 GHG emissions by 90% by FY2045 from a FY2022 base year. Eisai Europe Limited also commits to reduce absolute scope 3 GHG emissions by 90% within the same timeframe.
Statut
Targets setAnnée cible
FY2045
Statut
BA1.5 memberDate d'engagement
30/09/2021
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
LEI
21380063M56OQ1O3W564
Source : Science Based Targets initiative | Données publiques